An oral hypoglycemic agent is an inhibitor of sodium-dependent glucose transporter type 2.


Empagliflozin MS 25 mg.

Type 2 diabetes mellitus in adult patients with inadequate glycemic control in addition to diet and exercise:

  • as monotherapy;
  • as a combination therapy with other hypoglycemic drugs, including insulin.

The drug is indicated for patients with type 2 diabetes mellitus and high cardiovascular risk in combination with standard therapy for cardiovascular diseases to reduce:

  • overall mortality by reducing cardiovascular mortality;
  • cardiovascular mortality or hospitalization for heart failure.

High cardiovascular risk is defined as the presence of at least one of the following diseases and/or conditions:

  • IHD (history of myocardial infarction, coronary artery bypass surgery, IHD with damage to one coronary vessel, IHD with damage to several coronary vessels);
  • History of ischemic or hemorrhagic stroke;
  • Peripheral arterial disease (with or without symptoms).

Tablets should be taken orally with water. Can be taken at any time of the day, regardless of meals. Used for monotherapy or combination therapy for type 2 diabetes mellitus, as well as for the treatment of heart failure.

Recommended starting dose:

  • 10 mg 1 time per day.
  • If 10 mg does not provide adequate glycemic control, the dose may be increased to 25 mg once daily.

Maximum daily dose:

  • 25 mg.

When used concomitantly with sulfonylureas or insulin, dose adjustment may be required due to the risk of hypoglycemia.

If you miss a dose:

  • take the drug as soon as you remember.

A double dose should not be taken within one day.